Osteoarthritis (OA) is a disease of the joints that affects several million individuals worldwide. This disease, which involves mainly the diarthrodial joints, is chronic and develops slowly over decades, making it very difficult to precisely identify the different etiological and risk factors that influence its onset. At present, most therapies for OA are symptomatic. This review will focus on...

OBJECTIVE To study the association between metacarpal bone mineral density (BMD) loss and progressive hand osteoarthritis (OA) over 2 years. METHODS Using the Kellgren-Lawrence (KL) grading scale and the Osteoarthritis Research Society International Atlas, standardised hand radiographs of 181 patients with primary OA at multiple sites (mean age 60 years, 80% women, mean body mass index 27 kg/...

CONTEXT Viscosupplementation (VS) and physical therapy are both used to treat pain associated with knee osteoarthritis (OA). EVIDENCE ACQUISITION PubMed and EMBASE searches were performed to July 2013. Search terms included hyaluronic acid OR hylan, physical therapy OR exercise, AND osteoarthritis. STUDY DESIGN Clinical review. LEVEL OF EVIDENCE Level 4. RESULTS The efficacy and safety ...

Osteoarthritis (OA) can cause severe pain and dysfunction of the shoulder. When conservative treatment fails and operative treatments such as shoulder arthroplasty and open glenohumeral resurfacing are not advisable, shoulder arthroscopy may be used to treat shoulder OA. Arthroscopic treatment of concomitant pathology in the shoulder including subacromial decompression, labral repair, capsular ...

Osteoarthritis (OA) is the most common form of arthritis, affecting about 15% of persons over 60 years of age. Osteoarthritis is the most common cause of disability and a major source of pain and functional limitations. Up to one-half of people aged 50 and over report knee pain during the course of the year, and a quarter have severe and disabling pain. With the aging population and increasing ...

BACKGROUND Connective tissue growth factor (CTGF) has been implicated in development of osteoarthritis (OA). OBJECTIVE To determine the correlation between plasma and synovial fluid CTGF levels and the severity in knee osteoarthritis patients. METHODS A total of 100 subjects were recruited into this study (75 OA patients and 25 controls). CTGF concentrations in plasma and synovial fluid wer...

To assess the efficacy & safety of NilinTM SR tablets in the management of osteoarthritis of knee. 32 subjects from the age group 40-65 years having osteoarthritis of the knee, with no other rheumatologic condition were enrolled. Subjects were judged to have osteoarthritis with clinical diagnostic features; Knee pain for most days of the month, Morning stiffness of less than 30 minute duration,...

The Kennedy Institute of Rheumatology Symposium ‘Molecular Approaches to Osteoarthritis’ was held at Imperial College London on 18–20 April 2004. It encompassed current research into the molecular processes in cartilage underlying the initiation and progression of osteoarthritis (OA). The symposium also examined the potential impact on the field of new methodologies such as transcriptional prof...

OBJECTIVE To determine the comparative prevalence, associations with selected patient characteristics, and clinical outcomes of medial and lateral compartment patellofemoral (PF) joint osteoarthritis (OA). METHODS Information was collected by questionnaires, clinical assessment, and radiographs from 745 eligible community-dwelling symptomatic adults age ≥50 years. PF joint space narrowing (JS...

BACKGROUND Substance P (SP) is a pain- and inflammation-related neuropeptide which preferentially binds to the neurokinin receptor 1 (NK1 ). SP and NK1 receptors have been implicated in joint pain, inflammation and damage in animal models and human studies of osteoarthritis (OA). The aim of this study was to test if genetic variation at the neurokinin 1 receptor gene (TACR1) is associated with ...